Who is sponsoring NCT06122532?

NCT06122532 is sponsored by ShiCang Yu.

What drugs are being tested in NCT06122532?

Interventions in NCT06122532: Stem cell preparation combined with Reticular skin, Stem cell preparation combined with MEEK skin, Stem cell preparation combined with split-thickness skin, autologous skin grafting.

What condition does NCT06122532 study?

NCT06122532 studies Large Area Burns.

Is NCT06122532 still recruiting?

NCT06122532 is currently not yet recruiting. Last updated 8 November 2023.

Last reviewed 2023-11-08 · How we verify

NCT06122532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Umbilical Cord Mesenchymal Stem Cells for the Repair of Large Area Burn Wounds

Not yet recruiting NA Last updated 8 November 2023

What this trial tests

NA trial testing Stem cell preparation combined with Reticular skin in Large Area Burns in 20 participants. Not yet recruiting.

Timeline

20 December 2023

Primary endpoint
30 October 2028

30 October 2028

Quick facts

Lead sponsor	ShiCang Yu
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	20 December 2023
Primary completion	30 October 2028
Estimated completion	30 October 2028
Sites	1 location across China

Drugs / interventions tested

Stem cell preparation combined with Reticular skin
Stem cell preparation combined with MEEK skin
Stem cell preparation combined with split-thickness skin
autologous skin grafting

Conditions studied

Large Area Burns — all drugs for Large Area Burns →

Sponsor

ShiCang Yu

Who can join

Adults 18 to 65, any sex, with Large Area Burns. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to adopt a prospective, open, and randomized controlled research method to explore the effectiveness and safety of using human umbilical cord mesenchymal stem cells to treat large-scale burn wounds, in order to break through the limitations of various current treatment methods, explore new clinical treatment methods, promote the repair and healing of skin lesions, and further improve the cure rate and quality of life of patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Myofibroblast Fate of Therapeutic Mesenchymal Stromal Cells: Regeneration, Repair, or Despair?
Younesi FS, Hinz B. · · 2024 · cited 7× · PMID 39201399 · DOI 10.3390/ijms25168712

Verify or expand the search:

Other ShiCang Yu trials

Trials by the same sponsor.

NCT06171906 — Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 4 · not yet recruiting
NCT05676190 — Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer · NA · recruiting
NCT05319106 — Phase Ⅱ Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Venous Leg · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06122532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ShiCang Yu
Last refreshed: 8 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06122532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing